[ Inside the business ]

ALNY stock analysis

ALNY · Alnylam Pharmaceuticals, Inc.

Pharmaceutical preparations. Growing 17%. Keeps 20¢ of every dollar.

Watch: a leadership change, growth that has stopped speeding up.

The future, in 7 questions

Priced in: 1.5× sales in 5 yrs. Evidence: sales +17% · 20¢ profit/$1.

01 What's priced in?1.5× sales in 5 yrs
Sales now$5.0B
Needed in 5 yrs$7.8B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales +17%, steady
No customer over 10%
Prepaid $12MSales +17%, steady
04 Is it scarce?Some signs
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 20¢ per $1, rising
'21'22'23'24'2520¢
Before running costs: 86% → 82%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares +3.8%/yrDebt $0
07 What could break it?1 to watch
  • Growth slowing

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth slowing.

Sales growth +85%, +67%, then +17% vs. a year ago. A leadership change was filed on Nov 5.

What could go wrong

Steadier than most.

It has moved 0.7× the market. In the 2008 crisis it fell 42% while the market fell 51%. Debt is covered by cash.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

77% Amvuttra.

Amvuttra 77% · GIVLAARI 7% · Royalty 6% · Collaborations 5% · other

Where each dollar goes

20¢ profit.

23¢ to make what it sells, 58¢ on research and overhead, 20¢ left over. Revenue $5.0B in the last 12 months.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Growth.

It earns cash, invests heavily, and still raises money to grow.

Earnings quality

Some warning signs.

A few of its numbers drift toward the pattern of past manipulators. Cash covers 36¢ of each $1 of profit.

Competitive advantage

1 of 8 years.

Returns beat its 8.1% cost of capital in 1 of the last 8 years. Gross margin went from 100% to 82%.

Future bets

31% on research.

$1.6B a year on R&D. $150M on equipment and buildings.

All figures from Alnylam Pharmaceuticals, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.